- DaVita (NYSE:DVA) is showing an unusual mix of signals, with a Strong Buy Quant Rating alongside distress-level Altman Z-Score readings.
- The company reports robust revenue growth and margin expansion while insiders have been selling shares in meaningful amounts.
- This combination of financial strength indicators and red flags has not been covered in recent discussions of DaVita.
DaVita, a major provider of kidney care services, sits at the intersection of healthcare demand and reimbursement pressures that matter to long term investors. Recent commentary has highlighted its revenue profile and operating margins, which can be key for a business that depends on scale and tight cost control. In this operational context, the latest mix of balance sheet stress signals and insider selling adds a layer of complexity for anyone tracking NYSE:DVA.
For you as a shareholder or potential investor, the message is not straightforward. Strong revenue and margin trends, a supportive Quant Rating, a distress-level Altman Z-Score, and insider selling all point in different directions. It therefore becomes important to weigh upside drivers against financial risk indicators. The rest of this article focuses on laying out those moving pieces clearly so you can judge how this new information fits with your own risk tolerance and time horizon.
Stay updated on the most important news stories for DaVita by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on DaVita.
See which insiders are buying and buying and selling DaVita following this latest news.
Quick Assessment
- ⚖️ Price vs Analyst Target: At US$148.22 versus a consensus target of US$151.71, DaVita trades about 2% below analyst expectations, which is within the usual range.
- ✅ Simply Wall St Valuation: The shares are flagged as trading about 61.1% below estimated fair value, which is a strong value signal.
- ❌ Recent Momentum: The 30 day return of about 0.5% decline shows weak short term momentum.
There is only one way to know the right time to buy, sell or hold DaVita. Head to Simply Wall St's company report for the latest analysis of DaVita's Fair Value.
Key Considerations
- 📊 The mix of a Strong Buy Quant Rating, strong value signals and a distress level Altman Z-Score suggests you should weigh the upside case against balance sheet strain.
- 📊 Watch the P/E of 13.7 versus the Healthcare average of 22.1, the US$148.22 price against the US$151.71 target range of US$126 to US$190, and any updates to revenue growth or margins.
- ⚠️ The key flagged risk is that debt is not well covered by operating cash flow, which ties directly to the weak Altman Z-Score and makes leverage a central issue for this story.
Dig Deeper
For the full picture including more risks and rewards, check out the complete DaVita analysis. Alternatively, you can check out the community page for DaVita to see how other investors believe this latest news will impact the company's narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com